Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.

Annals of hematology - 1 Mar 2010

Sharma Pratibha, Kumar Lalit, Mohanty Sujata, Kochupillai Vinod

Abstract excerpt

Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond differently to Imatinib mesylate. This prompted us to study BCR-ABL transcripts in chronic myeloid leukemia (CML) patients and their correlation with response to Imatinib. Eighty-seven chronic phase CML patients (median age, 35 years; range, 13-62 years; M/F, 59:28) were included in this study; 57 patients had received...

Topics

Join the communities discussing this publication.

Benzamides
Cytogenetic Analysis
Fusion Proteins, bcr-abl
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Remission Induction

Source

Identifiers

PMID: 19714331
DOI: 10.1007/s00277-009-0822-7

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.PMID 19714331Read ↗

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirSemantic proximity Read ↗

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Semantic proximity Read ↗

A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.Semantic proximity Read ↗

[Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia].Semantic proximity Read ↗

Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.Semantic proximity Read ↗

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.Semantic proximity Read ↗

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.Semantic proximity Read ↗

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptSemantic proximity Read ↗

BCR/ABL rearrangement with b3a3 fusion transcript in a case of childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.Semantic proximity Read ↗

Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.